Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Martine Escoffre, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Herve Avet-Loiseau, Alexandra Jobert, Lucie Planche, Jill Corre, Philippe Moreau

Blood (2024) 143 (20): 2029–2036.

https://doi.org/10.1182/blood.2023023597

Published: 2024

Includes: Supplemental data

Journal Articles

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Olivier Decaux, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Jill Corre, Alexandra Jobert, Lucie Planche, Herve Avet-Loiseau, Philippe Moreau

Blood (2023) 142 (Supplement 1): 207.

https://doi.org/10.1182/blood-2023-174044

Published: 2023

Journal Articles

Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia: Why Do Adolescents and Young Adults Outcomes Differ from Those of Children? a Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)

Blood (2021) 138 (Supplement 1): 2921.

https://doi.org/10.1182/blood-2021-146769

Published: 2021

Journal Articles

Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM)

Philippe Moreau, MDPhD, Cyrille Hulin, MD, Denis Caillot, MD, Gerald Marit, MD, Aurore Perrot, MD, Laurent Garderet, MD PhD, Thierry Facon, MD, Lofti Benboubker, MD, Lionel Karlin, MD, Mourad Tiab, Bertrand Arnulf, MD PhD, Xavier Leleu, MD PhD, Cyrille Touzeau, MD PhD, Murielle Roussel, Lucie Planche, Hervé Avet-Loiseau, Thomas Dejoie, Michel Attal, MD PhD

Blood (2017) 130 (Supplement 1): 2021.

https://doi.org/10.1182/blood.V130.Suppl_1.2021.2021

Published: 2017

Journal Articles

Impact of Early Post-Transplant 5-Point Deauville Scale (18)F-FDG-PET Status on Survival Outcomes after Allogeneic Transplantation for Lymphoma

Louise Bouard, Caroline Bodet-Milin, Thierry Guillaume, MD PhD, Pierre Peterlin, MD, Clement Bailly, Alice Garnier, MD, Amandine Le Bourgeois, PhD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, Pierre Gallas, MD, Cyrille Touzeau, MD PhD, Thomas Gastinne, MD, Anne Lok, MD, Lucie Planche, Steven Le Gouill, MDPhD, Philippe Moreau, MDPhD, Francoise Kraeber-Bodere, Patrice Chevallier, MD

Blood (2017) 130 (Supplement 1): 3266.

https://doi.org/10.1182/blood.V130.Suppl_1.3266.3266

Published: 2017

Journal Articles

Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM)

Blood (2016) 128 (22): 674.

https://doi.org/10.1182/blood.V128.22.674.674

Published: 2016

Journal Articles

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Blood (2016) 127 (21): 2569–2574.

https://doi.org/10.1182/blood-2016-01-693580

Published: 2016

Journal Articles

Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial

Blood (2015) 126 (23): 393.

https://doi.org/10.1182/blood.V126.23.393.393

Published: 2015

Journal Articles

Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma

Philippe Moreau, Brigitte Kolb, Michel Attal, Denis Caillot, Lotfi Benboubker, Mourad Tiab, Cyrille Touzeau, Xavier Leleu, Murielle Roussel, Carine Chaleteix, Lucie Planche, Anne Chiffoleau, June Fortin, Hervé Avet-Loiseau, Jean-Yves Mary, Cyrille Hulin, Thierry Facon

Blood (2015) 125 (20): 3100–3104.

https://doi.org/10.1182/blood-2015-02-626168

Published: 2015

Journal Articles

Prospective Comparison Of Five Viral Infections (HHV6, CMV, EBV, ADV, BKv) After Umbilical Cord Blood (UCB) Vs PBSC Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation (allo-SCT) In Adults

Marina Illiaquer, PharmD, PhD Student, Berthe-Marie Imbert-Marcille, Pr, Lucie Planche, Marie Rimbert, Claire Le Houerou, Céline Bressollette-Bodin, MD, PhD, Thierry Guillaume, MD, Amandine Le Bourgeois, Jacques Delaunay, MD, Philippe Moreau, MD, Mohamad Mohty, MD, PhD, Patrice Chevallier, MD, PhD

Blood (2013) 122 (21): 3284.

https://doi.org/10.1182/blood.V122.21.3284.3284

Published: 2013

Journal Articles

Prognostic Impact of Hematopoietic Recovery After Fludarabine, IV Busulfan and Antithymocyte Globulins (FB2 regimen) Reduced-Intensity Conditioning Regimen (RIC) Allogeneic Stem Cell Transplantation (allo-SCT)

Blood (2012) 120 (21): 4483.

https://doi.org/10.1182/blood.V120.21.4483.4483

Published: 2012

Journal Articles

Higher HHV-6 Reactivation After Cord Blood Allo-SCT Is Not Related to HHV-6 Cell Receptor CD46 Expression

Patrice Chevallier, MD, Nelly Robillard, Marina Illiaquer, Julie Esbelin, Mohamad Mohty, MD PhD, Celine Bodin-Bressollette, Thierry Guillaume, MD, Veronique Stocco, MD, Fabienne Auffray, Sophie Derenne, Lucie Planche, Marie-christine Béné, Berthe-Marie Imbert-Marcille

Blood (2012) 120 (21): 1931.

https://doi.org/10.1182/blood.V120.21.1931.1931

Published: 2012

Journal Articles

Comparison of PBSC Vs Cord Blood (CB) As Stem Cells Source for Reduced-Intensity Conditioning Regimen (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) in Adult Patients with Haematological Diseases: A Single Centre Analysis.

Blood (2012) 120 (21): 3108.

https://doi.org/10.1182/blood.V120.21.3108.3108

Published: 2012

Journal Articles

The Combination of ISS 3, High LDH and t(4;14) and/or Del(17p) Identify a Simple Prognostic Index for Overall Survival in Patients Treated with Novel Agents-Based Induction Therapy and Front-Line Autologous Stem Cell Transplantation, and Allow the Definition of a Subgroup of Patients At High-Risk of Early Death From Progressive Disease

Blood (2012) 120 (21): 598.

https://doi.org/10.1182/blood.V120.21.598.598

Published: 2012

Journal Articles

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

Blood (2011) 117 (11): 3041–3044.

https://doi.org/10.1182/blood-2010-08-300863

Published: 2011

Journal Articles

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

Philippe Moreau, Arnaud Jaccard, Lotfi Benboubker, Bruno Royer, Xavier Leleu, Franck Bridoux, Gilles Salles, Veronique Leblond, Murielle Roussel, May Alakl, Olivier Hermine, Lucie Planche, Jean-Luc Harousseau, Jean-Paul Fermand

Blood (2010) 116 (23): 4777–4782.

https://doi.org/10.1182/blood-2010-07-294405

Published: 2010

Journal Articles

Features of Herpesviruses (CMV, EBV, HHV6) Infections and Immune Reconstitution after Allogeneic Stem Cell Transplantation (allo-SCT) Using Alternative Donors: Comparison Between Matched Unrelated Donors (MUD) and Cord Blood (CB) as Stem Cell Source.

Patrice Chevallier, Thierry Guillaume, Lucie Planche, Imen Hebia-Fellah, Celine Bressollette- Bodin, Fanny Rialland, Marianne Coste-Burel, Sameh Ayari, Jacques Delaunay, MD, Valerie Horvais, Jean-Luc Harousseau, Mohamad Mohty, MD, PhD, Berthe-Marie Imbert-Marcille

Blood (2008) 112 (11): 1148.

https://doi.org/10.1182/blood.V112.11.1148.1148

Published: 2008

Journal Articles

Interest of Non-Myeloablative Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: A Multicenter Retrospective Study.

Steven Le Gouill, MD, PhD, Nikolaus Kroeger, MD, Nathalie Dhedin, Arnon Nagler, Krimo Bouabdallah, Ibrahim Yakoub-Agha, MD, PhD, Claude-Eric Bulabois, Agnes Buzyn, Bernard Rio, Marie-Pierre Moles, Avichai Shimoni, Thierry Guillaume, Noel Milpied, MD, Lucie Planche, Jean-Luc Harousseau, MD, Mohamad Mohty, MD, PhD

Blood (2008) 112 (11): 1965.

https://doi.org/10.1182/blood.V112.11.1965.1965

Published: 2008

Journal Articles

Prognosis Value of [ 18 f] FDG-PET Prior Versus after Autologous Stem Cells Transplantation in High Grade Non-Hodgkin’s Lymphoma.

Virginie Roland, Caroline Bodet Milin, Anne Moreau, Thomas Gastinne, Beatrice Mahe, Viviane Dubruille, Hervé Maisonneuve, Nadine Morineau, Philippe Moreau, Henri Jardel, Lucie Planche, Philippe Moreau, Jean- Luc Harousseau, Françoise Kraeber bodere, Steven Le Gouill, MD, PhD

Blood (2008) 112 (11): 2177.

https://doi.org/10.1182/blood.V112.11.2177.2177

Published: 2008

Journal Articles

Prolonged PFS after Autologous Stem Cell Transplantation in Follicular Lymphoma Patients: A Long-Term Retrospective Study.

Violaine Safar, Thomas Gastinne, Noel Milpied, MD, Hervé Maisonneuve, Nadine Morineau, Viviane Dubruille, Beatrice Mahé, Philippe Moreau, Henri Jardel, Lucie Planche, Philippe Moreau, Jean-Luc Harousseau, Steven Le Gouill, MD

Blood (2008) 112 (11): 2190.

https://doi.org/10.1182/blood.V112.11.2190.2190

Published: 2008

NARROW

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia: Why Do Adolescents and Young Adults Outcomes Differ from Those of Children? a Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)

Impact of Early Post-Transplant 5-Point Deauville Scale (18)F-FDG-PET Status on Survival Outcomes after Allogeneic Transplantation for Lymphoma

Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM)

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial

Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma

Prospective Comparison Of Five Viral Infections (HHV6, CMV, EBV, ADV, BKv) After Umbilical Cord Blood (UCB) Vs PBSC Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation (allo-SCT) In Adults

Prognostic Impact of Hematopoietic Recovery After Fludarabine, IV Busulfan and Antithymocyte Globulins (FB2 regimen) Reduced-Intensity Conditioning Regimen (RIC) Allogeneic Stem Cell Transplantation (allo-SCT)

Higher HHV-6 Reactivation After Cord Blood Allo-SCT Is Not Related to HHV-6 Cell Receptor CD46 Expression

Comparison of PBSC Vs Cord Blood (CB) As Stem Cells Source for Reduced-Intensity Conditioning Regimen (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) in Adult Patients with Haematological Diseases: A Single Centre Analysis.

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

Features of Herpesviruses (CMV, EBV, HHV6) Infections and Immune Reconstitution after Allogeneic Stem Cell Transplantation (allo-SCT) Using Alternative Donors: Comparison Between Matched Unrelated Donors (MUD) and Cord Blood (CB) as Stem Cell Source.

Interest of Non-Myeloablative Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: A Multicenter Retrospective Study.

Prognosis Value of [ 18 f] FDG-PET Prior Versus after Autologous Stem Cells Transplantation in High Grade Non-Hodgkin’s Lymphoma.

Prolonged PFS after Autologous Stem Cell Transplantation in Follicular Lymphoma Patients: A Long-Term Retrospective Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only